There is emerging scientific interest in the potential role of Bifidobacterium (mixed species) in supporting the management of psoriasis, but the evidence to date is limited and preliminary. Psoriasis is a chronic inflammatory skin condition with immune system involvement, and recent research suggests that the gut-skin axis and alterations in gut microbiota might play a role in its pathogenesis. Some studies have shown that individuals with psoriasis often have gut dysbiosis, characterized by reduced diversity and abundance of beneficial bacteria, including Bifidobacterium species.

A few small-scale clinical trials and animal studies have explored the effects of probiotic supplementation, including Bifidobacterium, in psoriasis. For example, a 2013 open-label trial (Groeger et al.) using a combination of Lactobacillus salivarius and Bifidobacterium infantis found modest improvements in markers of inflammation in patients with psoriasis, but the study was small and not placebo-controlled. Another pilot study (2019) showed some reduction in psoriasis severity with multi-strain probiotics (including Bifidobacterium), but again, the sample sizes were limited and methodologies varied.

Overall, while there is a scientific rationale based on the gut-skin connection and some early clinical data, high-quality, large-scale randomized controlled trials are lacking. Thus, Bifidobacterium (mixed) as an adjunct for psoriasis treatment is supported by limited scientific evidence, and its use should be considered experimental at this stage.